- This topic has 38 replies, 13 voices, and was last updated 13 years, 2 months ago by
.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dear dear dear, having a caps hissy fit now are we? I don't get it Jake, first you ask, "why take up the space here? There are more important things to "grab the headlines." Then you proceed to bring the whole issue back to the top of the board and refer (yet again) to a doctor (Nicholas Gonzalez ) you spoke with two years ago. And let's not forget those two inspirational patients you may have met, one of whom is sadly now dead, and another, you have not spoken to in two whole years. (Doesn’t sound very confidence inspiring to me. )
I sure hope this chart shows up, evidently it's a snapshot of your hero's one clinical trial. ( I recall you ended your mango post with the words.. "I am a proponent of "whatever works for that individual" – well, with documented results like these Jake, it sure looks like Gonzalez is not your man then after all eh.)
Let's have a bit more of that warm support, guidance, information, etc., etc., etc., et from you Jake. And less tantrums please. And for the record, Nic is a genus ….and a most compassionate, generous and now zen one at that!
Patients in the two groups responded similarly to the questionnaires on quality of life before initiation of therapy, but the overall FACT-PA scores during 12 months decreased more in the enzyme group than in the gemcitabine group (Fig 3). Twenty-four percent of total measurements were missing. Quality of life scores of both groups were significantly different (P.01). During the first 6 months of the study, pain scores increased in the enzyme group, but they decreased in the chemotherapy group (P.05); however, few patients reported on use of analgesics. (Table 2).
http://jco.ascopubs.org/content/28/12/2058.abstract
Abstract
Purpose Conventional medicine has had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patients seek alternative treatments. The National Cancer Institute, in 1998, sponsored a randomized, phase III, controlled trial of proteolytic enzyme therapy versus chemotherapy. Because most eligible patients refused random assignment, the trial was changed in 2001 to a controlled, observational study.
Methods All patients were seen by one of the investigators at Columbia University, and patients who received enzyme therapy were seen by the participating alternative practitioner. Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-based chemotherapy, and 32 elected enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet. Primary and secondary outcomes were overall survival and quality of life, respectively.
Results At enrollment, the treatment groups had no statistically significant differences in patient characteristics, pathology, quality of life, or clinically meaningful laboratory values. Kaplan-Meier analysis found a 9.7-month difference in median survival between the chemotherapy group (median survival, 14 months) and enzyme treatment groups (median survival, 4.3 months) and found an adjusted-mortality hazard ratio of the enzyme group compared with the chemotherapy group of 6.96 (P < .001). At 1 year, 56% of chemotherapy-group patients were alive, and 16% of enzyme-therapy patients were alive. The quality of life ratings were better in the chemotherapy group than in the enzyme-treated group (P < .01).
Conclusion Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long (14.0 v 4.3 months) and had better quality of life than those who chose proteolytic enzyme treatment.
-
Dear dear dear, having a caps hissy fit now are we? I don't get it Jake, first you ask, "why take up the space here? There are more important things to "grab the headlines." Then you proceed to bring the whole issue back to the top of the board and refer (yet again) to a doctor (Nicholas Gonzalez ) you spoke with two years ago. And let's not forget those two inspirational patients you may have met, one of whom is sadly now dead, and another, you have not spoken to in two whole years. (Doesn’t sound very confidence inspiring to me. )
I sure hope this chart shows up, evidently it's a snapshot of your hero's one clinical trial. ( I recall you ended your mango post with the words.. "I am a proponent of "whatever works for that individual" – well, with documented results like these Jake, it sure looks like Gonzalez is not your man then after all eh.)
Let's have a bit more of that warm support, guidance, information, etc., etc., etc., et from you Jake. And less tantrums please. And for the record, Nic is a genus ….and a most compassionate, generous and now zen one at that!
Patients in the two groups responded similarly to the questionnaires on quality of life before initiation of therapy, but the overall FACT-PA scores during 12 months decreased more in the enzyme group than in the gemcitabine group (Fig 3). Twenty-four percent of total measurements were missing. Quality of life scores of both groups were significantly different (P.01). During the first 6 months of the study, pain scores increased in the enzyme group, but they decreased in the chemotherapy group (P.05); however, few patients reported on use of analgesics. (Table 2).
http://jco.ascopubs.org/content/28/12/2058.abstract
Abstract
Purpose Conventional medicine has had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patients seek alternative treatments. The National Cancer Institute, in 1998, sponsored a randomized, phase III, controlled trial of proteolytic enzyme therapy versus chemotherapy. Because most eligible patients refused random assignment, the trial was changed in 2001 to a controlled, observational study.
Methods All patients were seen by one of the investigators at Columbia University, and patients who received enzyme therapy were seen by the participating alternative practitioner. Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-based chemotherapy, and 32 elected enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet. Primary and secondary outcomes were overall survival and quality of life, respectively.
Results At enrollment, the treatment groups had no statistically significant differences in patient characteristics, pathology, quality of life, or clinically meaningful laboratory values. Kaplan-Meier analysis found a 9.7-month difference in median survival between the chemotherapy group (median survival, 14 months) and enzyme treatment groups (median survival, 4.3 months) and found an adjusted-mortality hazard ratio of the enzyme group compared with the chemotherapy group of 6.96 (P < .001). At 1 year, 56% of chemotherapy-group patients were alive, and 16% of enzyme-therapy patients were alive. The quality of life ratings were better in the chemotherapy group than in the enzyme-treated group (P < .01).
Conclusion Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long (14.0 v 4.3 months) and had better quality of life than those who chose proteolytic enzyme treatment.
-
-
-
-
-
-
-
-
-
-
-
-
- You must be logged in to reply to this topic.